Literature DB >> 31220742

Clinical course of infectious intracranial aneurysm undergoing antibiotic treatment.

Cory J Rice1, Sung-Min Cho2, Robert J Marquardt1, Lucy Q Zhang1, Jean Khoury1, Julian Hardman1, Dolora Wisco1, M Shazam Hussain1, Ken Uchino3.   

Abstract

INTRODUCTION: Infectious intracranial aneurysm (IIA, or mycotic aneurysm) is a cerebrovascular complication of infective endocarditis. We aimed to describe the clinical course of IIAs during antibiotic treatment.
METHODS: We reviewed medical records of persons with infective endocarditis who underwent cerebral angiography at a single tertiary referral center from 2011 to 2016. Aneurysms were followed with subsequent angiography for unfavorable outcome (growth, rupture, no change, or new IIA formation) or favorable outcome (regression or resolution) until endovascular therapy, aneurysm resolution, or end of observation.
RESULTS: Of 618 patients included, 40 (6.5%) had 43 IIAs. Eighteen (42%) aneurysms underwent initial endovascular treatment. Twenty-five unruptured aneurysms were followed for a median 18 antibiotic days after IIA discovery (interquartile range [IQR] 4-32). Eleven (44%) aneurysms had unfavorable outcome (1 rupture, 2 new IIA formation, 6 enlargement, and 2 no change) at median 21 days (IQR 5-32). Favorable angiographic outcome was seen in 7 (28%) patients (6 resolution, 1 regression) at median 36 days (IQR 24-41). Seven aneurysms had no angiographic reevaluations but showed no evidence of rupture during clinical follow-up for median 4 days (IQR 3-12) until hospital discharge. Saccular morphology was associated with unfavorable aneurysmal outcome (p = 0.013). Longer duration of antibiotic exposure prior to IIA discovery was associated with favorable aneurysmal outcome (p = 0.046).
CONCLUSION: IIAs represent a dynamic disease. Only a quarter of IIAs resolve with antibiotics alone. Saccular aneurysmal morphology might predict unfavorable aneurysmal outcome. IIA found after longer antibiotic therapy has higher likelihood of resolution or regression on antibiotic treatment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiogram; Antibiotics; Infectious intracranial aneurysm

Year:  2019        PMID: 31220742     DOI: 10.1016/j.jns.2019.06.004

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

1.  Endovascular treatment of infectious intracranial aneurysms complicating infective endocarditis: a series of 31 patients with 55 aneurysms.

Authors:  Fabiola Serrano; Alexis Guédon; Jean-Pierre Saint-Maurice; Marc-Antoine Labeyrie; Vittorio Civelli; Michael Eliezer; Emmanuel Houdart
Journal:  Neuroradiology       Date:  2021-08-30       Impact factor: 2.804

2.  Neurological Outcomes of Patients With Mycotic Aneurysms in Infective Endocarditis.

Authors:  Hang Shi; Neal S Parikh; Charles Esenwa; Richard Zampolin; Harsh Shah; Farid Khasiyev; Ives Valenzuela; Sean Lavine; Jose Gutierrez; Joshua Willey
Journal:  Neurohospitalist       Date:  2020-06-15

3.  Case report: Meningitis and intracranial aneurysm caused by mixed infection of oral microflora dominated by anaerobes.

Authors:  Hongjiang Cheng; Lina Xu; Fengbing Yang; Longbin Jia; Doudou Zhao; Huimin Li; Wei Liu; Yujuan Li; Xiaoli Liu; Xia Geng; Jiaying Guo; Chen Ling; Jing Zhang
Journal:  Front Neurol       Date:  2022-08-05       Impact factor: 4.086

4.  Simultaneous intracerebral and subarachnoid hemorrhages caused by multiple infectious intracranial aneurysms treated endovascularly and by microsurgical clipping: illustrative case.

Authors:  Ken Akimoto; Kiyoyuki Yanaka; Kazuhiro Nakamura; Hayato Takeda; Minami Saura; Maya Takada; Hisayuki Hosoo; Yuji Matsumaru; Eiichi Ishikawa
Journal:  J Neurosurg Case Lessons       Date:  2022-02-14

5.  Risk factors of intracranial infection in patients after intracranial aneurysm surgery: Implication for treatment strategies.

Authors:  Xiaohong Guo; Junkang Fang; Yi Wu
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.